Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Antibody drug conjugates coming to primetime and new agents for breast cancer

Dr Mariana Chavez McGregor - MD Anderson Cancer Center, Houston, USA
Antibody drug conjugates coming to primetime and new agents for breast cancer ( Dr Mariana Chavez McGregor - MD Anderson Cancer Center, Houston, USA )
12 Jul 2024

Pancreatic, hepatic and biliary malignancies

Dr Mike Cusnir - Mount Sinai Medical Center, Miami, USA
Pancreatic, hepatic and biliary malignancies ( Dr Mike Cusnir - Mount Sinai Medical Center, Miami, USA )
12 Jul 2024

Intervention of osteoclastogenesis that occurs in breast cancer and multiple myeloma

Dr Gregg Fields - Florida Atlantic University, Florida, USA
Intervention of osteoclastogenesis that occurs in breast cancer and multiple myeloma ( Dr Gregg Fields - Florida Atlantic University, Florida, USA )
12 Jul 2024

Uncommon genetic aberrations NTRK, RET, NRG

Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA
Uncommon genetic aberrations NTRK, RET, NRG ( Dr Luis E. Raez - Memorial Cancer Institute, Miami, USA )
12 Jul 2024

Updates on triple negative breast cancer and immunotherapy

Dr Avan Armaghani - Moffitt Cancer Center, Florida, Miami
Updates on triple negative breast cancer and immunotherapy ( Dr Avan Armaghani - Moffitt Cancer Center, Florida, Miami )
12 Jul 2024

Pembrolizumab combined with xelox and bevacizumab shows higher efficacy than standard therapeutic regimen in mCRC

Prof David Tougeron - Poitiers University Hospital, Poitiers, France
Pembrolizumab combined with xelox and bevacizumab shows higher efficacy than standard therapeutic regimen in mCRC ( Prof David Tougeron - Poitiers University Hospital, Poitiers, France )
9 Jul 2024

Paclitaxel and ramucirumab switch maintenance therapy prolongs survival in HER2-negative advanced GEJ cancer

Dr Giovanni Randon - The National Cancer Institute of Milan, Milano, Italy
Paclitaxel and ramucirumab switch maintenance therapy prolongs survival in HER2-negative advanced GEJ cancer ( Dr Giovanni Randon - The National Cancer Institute of Milan, Milano, Italy )
9 Jul 2024

Administering systemic chemotherapy improves survival for patients with resectable CRCLM

Dr Giacomo Bregni - Francis Crick Institute, London, England
Administering systemic chemotherapy improves survival for patients with resectable CRCLM ( Dr Giacomo Bregni - Francis Crick Institute, London, England )
9 Jul 2024

Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma

Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA
Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma ( Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA )
9 Jul 2024

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia

Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia ( Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany )
27 Jun 2024

Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant

Dr Kevin Kalinsky - Winship Cancer Institute, Georgia, USA
Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant ( Dr Kevin Kalinsky - Winship Cancer Institute, Georgia, USA )
26 Jun 2024

Isa-VCd induction in NDMM patients with severe renal impairment show no new safety concerns

Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece
Isa-VCd induction in NDMM patients with severe renal impairment show no new safety concerns ( Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece )
26 Jun 2024